Open Access Green möglich sobald Postprint bei der ZB eingereicht worden ist.
Essential role of radiation therapy for the treatment of pancreatic cancer.
Strahlenther. Onkol. 194, 185–195 (2018)
Pancreatic cancer is one of the most aggressive human tumors and the incidence has increased over the last 6 years. In the majority of cases the disease is already in an advanced stage at the time of diagnosis where surgery, the only curative treatment, is no longer an option and explains the still abysmal overall survival. The role of radiation therapy as treatment option for patients with pancreatic cancer is controversially discussed although radiation oncology has emerged as a central pillar in the combined oncological treatment. The present manuscript gives an overview of advanced radiotherapeutic strategies in the context of chemotherapy and surgery according to the current American Society of Clinical Oncology (ASCO) guidelines in comparison with the German guidelines and to elucidate the role of radiation therapy for the treatment of pancreatic cancer. Advanced modern radiotherapeutic techniques in combination with individualized high-precision radiation concepts are new therapeutic approaches for pancreatic cancer in a multimodal setting with tolerable side effects. Several clinical studies together with experimental approaches are in process, to deliver further evidence and ultimately allow true personalized medicine.
Impact Factor
Scopus SNIP
Web of Science
Times Cited
Times Cited
Scopus
Cited By
Cited By
Altmetric
2.459
1.023
16
15
Anmerkungen
Besondere Publikation
Auf Hompepage verbergern
Publikationstyp
Artikel: Journalartikel
Dokumenttyp
Wissenschaftlicher Artikel
Schlagwörter
Intensity Modulated Radiotherapy ; Disease-free Survival ; Stereotactic Radiosurgery ; Clinical Studies ; Interdisciplinary Treatment; Stereotactic Body Radiotherapy; Gemcitabine-based Chemoradiation; Clinical-practice Guideline; Phase-iii Trial; Neoadjuvant Chemoradiation; Intraoperative Radiotherapy; Resectable Adenocarcinoma; Preoperative Gemcitabine; Retrospective Analysis; Adjuvant Radiotherapy
Sprache
Veröffentlichungsjahr
2018
Prepublished im Jahr
2017
HGF-Berichtsjahr
2017
ISSN (print) / ISBN
0179-7158
e-ISSN
1439-099X
Quellenangaben
Band: 194,
Heft: 3,
Seiten: 185–195
Verlag
Urban & Vogel
Verlagsort
Heidelberg
Begutachtungsstatus
Peer reviewed
Institut(e)
Institute of Radiation Medicine (IRM)
POF Topic(s)
30203 - Molecular Targets and Therapies
Forschungsfeld(er)
Radiation Sciences
PSP-Element(e)
G-501300-001
WOS ID
WOS:000425741600001
Scopus ID
85032901648
PubMed ID
29094172
Erfassungsdatum
2017-11-15